Issues in hypertension: drug tolerability and special populations.
about
Using routinely collected prescribing data to determine drug persistence for the purpose of pharmacovigilance.Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR studyManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.Host gender in parasitic infections of mammals: an evaluation of the female host supremacy paradigm.Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD).Angiotensin receptor blockers in clinical practice--implications of the ONTARGET study.No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region.QUICKI is a useful index of insulin sensitivity in subjects with hypertension.Using primary care prescribing databases to determine drug switching and continuation of care.Diabetic retinopathy is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients.Hyperhomocysteinaemia is a significant risk factor for white matter lesions in Japanese type 2 diabetic patients.Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSC
P2860
Q33558310-E5B53649-1C4A-4582-A2D4-97E0DCA22406Q34018789-4DB1BF8A-3A69-4A3E-A70E-2D467C8DD5D9Q34134884-7C36BFBB-A218-40FE-AC46-39F20CB1D37EQ34673504-A3B302EE-1CC0-4536-9DE6-D6F564D91873Q35843344-75F81087-877B-4FB6-AE32-1BF4869D2694Q37328828-49C01826-C83E-4F16-A254-D815280189FDQ37994859-C00F09F4-8D78-4F03-96DC-650239F917F2Q39162849-2B6B1328-60E0-4636-AEDD-ED7D83B18E4AQ44391891-DFB069B9-B073-4930-9EE5-BC9DCA103777Q44509977-2E1388C3-6DD1-4BE1-9879-7B0C19BAB59FQ46099822-19C3E04A-0323-4366-AF45-CDED0627AE31Q46741003-A13735D6-BBD6-4680-B05B-DFCA6BD34102Q50771406-AF700828-3238-49F9-9F6F-9F0B11598741
P2860
Issues in hypertension: drug tolerability and special populations.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Issues in hypertension: drug tolerability and special populations.
@ast
Issues in hypertension: drug tolerability and special populations.
@en
Issues in hypertension: drug tolerability and special populations.
@nl
type
label
Issues in hypertension: drug tolerability and special populations.
@ast
Issues in hypertension: drug tolerability and special populations.
@en
Issues in hypertension: drug tolerability and special populations.
@nl
prefLabel
Issues in hypertension: drug tolerability and special populations.
@ast
Issues in hypertension: drug tolerability and special populations.
@en
Issues in hypertension: drug tolerability and special populations.
@nl
P1476
Issues in hypertension: drug tolerability and special populations.
@en
P2093
P304
P356
10.1016/S0895-7061(01)02132-X
P433
P577
2001-07-01T00:00:00Z